MediWound (NASDAQ:MDWD) Announces Earnings Results
MediWound reported quarterly earnings with an EPS of ($0.24), surpassing analysts' expectations of ($0.81). Despite a negative net margin of 142.18% and return on equity of 96.71%, the stock opened at $17.71. Institutional investors hold 46.83% of the stock. Analysts have a consensus rating of 'Moderate Buy' with a target price of $32.25.
MediWound (NASDAQ:MDWD - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.57, Zacks reports. MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%.
MediWound Price Performance
MediWound stock opened at $17.71 on Thursday. MediWound has a 12-month low of $14.14 and a 12-month high of $22.50. The stock has a market capitalization of $196.40 million, a PE ratio of -6.67 and a beta of 0.22. The firm has a 50 day simple moving average of $18.08 and a 200-day simple moving average of $18.85.
Hedge Funds Weigh In On MediWound
A number of hedge funds have recently modified their holdings of the stock. Rhumbline Advisers increased its holdings in MediWound by 4.4% in the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company's stock worth $176,000 after buying an additional 481 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 649 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 723 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock worth $85,000 after buying an additional 999 shares during the last quarter. Finally, Sargent Investment Group LLC lifted its position in shares of MediWound by 11.1% in the third quarter. Sargent Investment Group LLC now owns 59,926 shares of the biopharmaceutical company's stock worth $1,080,000 after buying an additional 6,000 shares during the last quarter. 46.83% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on MDWD shares. Weiss Ratings reissued a "sell (d-)" rating on shares of MediWound in a report on Wednesday, October 8th. Zacks Research raised MediWound from a "strong sell" rating to a "hold" rating in a report on Tuesday, November 11th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, MediWound has a consensus rating of "Moderate Buy" and a consensus target price of $32.25.
Read Our Latest Stock Report on MDWD
About MediWound
(Get Free Report)MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
See Also
- Five stocks we like better than MediWound
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- NVIDIA Just Proved the AI Boom Is Bigger Than Anyone Thought
- Where Do I Find 52-Week Highs and Lows?
- Why Target Stock May Keep Falling Despite a 5% Dividend Yield
- Transportation Stocks Investing
- Is Tesla Setting Up for a Year-End Rebound—or a Collapse?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in MediWound Right Now?
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
